Aquinox Pharmaceuticals Inc.’s (AQXP) phase II clinical trial investigating the ability of 200mg oral, once daily AQX-1125 to reduce pain in female patients with bladder pain syndrome/interstitial cystitis, or BPS/IC, has not met the statistical endpoint.